What's Happening?
Anixa Biosciences, a biotechnology company, announced that Dr. Robert Wenham, Chair of the Gynecologic Oncology Department at Moffitt Cancer Center, will present the status of their ongoing Phase 1 clinical trial of lira-cel at the Society of Gynecologic Oncology Annual
Meeting on Women's Cancer. The trial involves autologous T cells genetically engineered with a chimeric receptor to target the follicle-stimulating hormone receptor (FSHR) in recurrent ovarian cancer. The meeting, which is a significant event for professionals in gynecologic oncology, will take place from April 10 to 13, 2026, in San Juan, Puerto Rico.
Why It's Important?
The presentation of Anixa's trial at a major oncology meeting highlights the potential of CAR-T therapy in treating recurrent ovarian cancer, a condition with limited treatment options. The trial's focus on targeting FSHR, which is selectively expressed on ovarian cells and certain cancer cells, represents a novel approach in cancer immunotherapy. Success in this trial could lead to new treatment avenues for ovarian cancer, potentially improving outcomes for patients who have exhausted other therapies. The collaboration with Moffitt Cancer Center, a leader in cancer immunotherapy, underscores the trial's significance in advancing cancer treatment.
What's Next?
The ongoing Phase 1 trial is enrolling adult women with recurrent ovarian cancer who have progressed after at least two prior therapies. The results of this trial will be crucial in determining the future development of lira-cel. If successful, the trial could pave the way for further clinical trials and eventual regulatory approval. The presentation at the SGO meeting will likely attract attention from the medical community, potentially influencing future research and collaborations in the field of gynecologic oncology.
